ChiCTR2100048548 版本V1.1 版本创建时间2022/03/19 12:30:03 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100048548 

最近更新日期:

Date of Last Refreshed on:

2022-02-22 20:45:18 

注册时间:

Date of Registration:

2021-07-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

新生儿脑发育及其影响因素的超声脑功能成像研究

Public title:

Study of neonatal brain development with functional ultrasound

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新生儿脑发育及其影响因素的超声脑功能成像研究

Scientific title:

Study of neonatal brain development with functional ultrasound

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

周发亮 

研究负责人:

刘黎黎 

Applicant:

Zhou Faliang 

Study leader:

Liu Lili 

申请注册联系人电话:

Applicant telephone:

+86 16601117784

研究负责人电话:

Study leader's telephone:

+86 13810536759

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zflhfing@163.com

研究负责人电子邮件:

Study leader's E-mail:

liulili0205@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区西什库大街8号

研究负责人通讯地址:

北京市西城区西什库大街8号

Applicant address:

8 Xishiku Street, Xicheng District, Beijing

Study leader's address:

8 Xishiku Street, Xicheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学第一医院

Applicant's institution:

Peking University First Hospital

研究负责人所在单位:

北京大学第一医院

Affiliation of the Leader:

Peking University First Hospital

是否获伦理委员会批准:

否/No

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学第一医院儿科

Primary sponsor:

Peking University First Hospital pediatric department

研究实施负责(组长)单位地址:

北京市西城区西什库大街8号

Primary sponsor's address:

8 Xishiku Street, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第一医院

具体地址:

西城区西什库大街8号

Institution
hospital:

Peking University First Hospital

Address:

8 Xishiku street, Xicheng District

经费或物资来源:

Source(s) of funding:

N/A

Target disease:

neonatal brain development

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

主要目的: 1.正常新生儿脑发育的超声功能成像特点; 2.脑损伤新生儿的超声功能成像特点; 3.超声脑功能成像技术与床旁脑电图等其他脑功能检查方法的一致性; 4.评估超声脑功能成像技术在神经系统发育预后预测中的价值。  

Objectives of Study:

Main purpose: 1. Ultrasound functional imaging characteristics of normal neonatal brain development; 2. Ultrasound functional imaging characteristics of brain-injured neonates; 3. The consistency of ultrasound brain function imaging technology with other brain function examination methods such as bedside EEG; 4. To evaluate the value of ultrasound functional brain imaging technology in predicting the prognosis of nervous system development.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.新生儿惊厥;
3.3-4度颅内出血;
2.脑梗死;
4.脑积水(出血后、感染后、代谢性等);
5.中-重度新生儿缺氧缺血性脑病;
6.围产期脑卒中,胆红素脑病;
7.新生儿细菌性脑膜炎;
8.代谢性脑病;
9.脑发育畸形。

Inclusion criteria

1. Neonatal convulsions;
3. 3-4 degree intracranial hemorrhage;
2. Cerebral infarction;
4. Hydrocephalus (post-bleeding, post-infection, metabolic, etc.);
5. Moderate to severe neonatal hypoxic-ischemic encephalopathy;
6. Perinatal stroke, bilirubin encephalopathy;
7. Neonatal bacterial meningitis;
8. Metabolic encephalopathy;
9. Brain developmental malformations.

排除标准:

1.在数据采集过程中,被试哭闹难以安抚,使采集不能完成者;
2.被试新生儿存在囟门处头皮破损、感染,不能完成数据采集者;
3.家属拒绝参与研究。

Exclusion criteria:

1. Those cry and are difficult to be soothed during the data collection process, making this process impossible to complete;
2. Those who had scalp breakage or infection at fontanelle, making it impossible to complete data collection;
3. The family members refused to participate in the study.

研究实施时间:

Study execute time:

From 2021-07-10 00:00:00 To 2022-07-10 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-07-10 00:00:00 To 2025-07-10 00:00:00  

干预措施:

Interventions:

组别:

Case series

样本量:

40

Group:

Case series

Sample size:

干预措施:

干预措施代码:

Intervention:

No

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京大学第一医院 

单位级别:

三级甲等 

Institution
hospital:

Peking University First Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

脑血容量变化值

指标类型:

主要指标

Outcome:

Changes in cerebral blood volume

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

符合纳入标准均可

Randomization Procedure (please state who generates the random number sequence and by what method):

anyone acccording with the inclusion criteria

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

N/A

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

基于个体化的病例记录以及检查结果

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

case records and results for every patients

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-07-10 21:53:23